Paris, France et Camberley, Royaume-Uni – 30 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir de faire le point sur le nouveau test de détection du coronavirus (COVID-19) mis au point par Primerdesign, la division de diagnostic moléculaire du Groupe basée au Royaume-Uni. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-mise-à-jour-sur-le-test-pour-le-coronavirus-FRENCH-30.03.20.pdf
Visit PageNews and Events
Coronavirus test update, Sales and manufacturing update and COVID-19 test approved in India and Argentina
Paris, France and Camberley, UK – 30 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, the Company’s molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-COVID-19-test-update-ENGLISH-30.03.20.pdf
Visit PageAccord de distribution mondial avec Bruker pour le test de diagnostic COVID-19 Le test COVID-19 reçoit l’approbation de la Food and Drug Administration aux Philippines
Paris, France et Camberley, Royaume-Uni – 25 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce que Primerdesign, sa division de diagnostics moléculaires, a signé un accord de distribution mondiale pour son test COVID-19 avec Bruker-Hain Diagnostics, l’unité commerciale de produits de diagnostics moléculaires de Bruker Corporation
Visit PageSignature d’un accord de fabrication sous contrat avec Yourgene Health Plc Accroissement de la capacité de production pour soutenir la demande du test COVID-19 de Novacyt
Paris, France et Camberley, Royaume-Uni – 25 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer suite à l’annonce du 20 mars 2020, que la société a signé un accord de fabrication sous contrat avec Yourgene Health Plc (“Yourgene”) (AIM : YGEN), un groupe
Visit PageGlobal distribution agreement with Bruker for COVID-19 diagnostic test COVID-19 test receives FDA approval in the Philippines
Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker). http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update_Bruker-ENGLISH-25.03.20.pdf
Visit PageContract manufacturing services agreement signed with Yourgene Health Plc Additional manufacturing capacity to support demand for Novacyt’s COVID-19 diagnostic test
Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.
Visit PageAutorisation d’utilisation d’urgence de la FDA aux Etats-Unis du test pour le COVID-19 Approbation en Indonésie du test COVID-19 RUO
Paris, France et Camberley, Royaume-Uni – 23 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que la Food and Drug Administration (FDA) des États-Unis a délivré une autorisation d’utilisation d’urgence (Emergency Use Authorization, EUA) pour son test COVID-19. En conséquence, les hôpitaux et
Visit PageUS FDA Emergency Use Authorization for COVID-19 diagnostic test COVID-19 RUO test receives approval in Indonesia
Paris, France and Camberley, UK – 23 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test. As a result, hospitals and laboratories in the US will
Visit PageMise à jour sur le test pour le coronavirus Augmentation significative de la demande Poursuite de l’expansion des capacités de production
Paris, France et Camberley, Royaume-Uni – 20 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir de faire le point sur le nouveau test de détection du coronavirus (COVID-19) mis au point par Primerdesign, sa division de diagnostic moléculaire basée au Royaume-Uni. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-mise-à-jour-sur-le-test-pour-le-coronavirus-FRENCH-20.03.20.pdf
Visit PageCoronavirus test update Significant increase in demand Further expansion of manufacturing capacity
Paris, France and Camberley, UK – 20 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update-ENGLISH-20.03.20-Final.pdf
Visit Page